https://orcid.org/0000-0003-0869-4660
References
- Clinical updates in women’s health care summary: liver disease: reproductive considerations. Obstet Gynecol. 2017;129(1):236.
- Brouwers L, Koster MP, Page-Christiaens GC, et al. Intrahepatic cholestasis of pregnancy: maternal and fetal outcomes associated with elevated bile acid levels. Am J Obstet Gynecol. 2015;212(1):100 e1–7.
- Fisk NM, Storey GN. Fetal outcome in obstetric cholestasis. Br J Obstet Gynaecol. 1988;95(11):1137–1143.
- Geenes V, Chappell LC, Seed PT, et al. Association of severe intrahepatic cholestasis of pregnancy with adverse pregnancy outcomes: a prospective population-based case-control study. Hepatology. 2014;59(4):1482–1491.
- Glantz A, Marschall HU, Mattsson LA. Intrahepatic cholestasis of pregnancy: relationships between bile acid levels and fetal complication rates. Hepatology. 2004;40(2):467–474.
- Alsulyman OM, Ouzounian JG, Ames-Castro M, et al. Intrahepatic cholestasis of pregnancy: perinatal outcome associated with expectant management. Am J Obstet Gynecol. 1996;175(4):957–960.
- Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518–526.
- Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011;53(3):726–736.
- Tolunay HE, Kahraman NÇ, Varlı EN, et al. First-trimester aspartate aminotransferase to platelet ratio index in predicting intrahepatic cholestasis in pregnancy and its relationship with bile acids: a pilot study. Eur J Obstet Gynecol Reprod Biol. 2021;256:114–117.
- Tolunay HE, Kahraman NC, Varli EN, et al. Can first-trimester AST to platelet ratio index scores predict HELLP syndrome? Age (years). 2021;31:6.05.
- Şaşmaz Mİ, Ayvaz MA, Dülger AC, et al. Aspartate-aminotransferase to platelet ratio index score for predicting HELLP syndrome. Am J Emerg Med. 2020;38(3):459–462.
- Ovadia C, Seed PT, Sklavounos A, et al. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses. Lancet. 2019;393(10174):899–909.
- Faul F, Erdfelder E, Lang A-G, et al. G* power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175–191.
- Pathak B, Sheibani L, Lee RH. Cholestasis of pregnancy. Obstet Gynecol Clin North Am. 2010;37(2):269–282.
- Oztas E, Erkenekli K, Ozler S, et al. Can routine laboratory parameters predict adverse pregnancy outcomes in intrahepatic cholestasis of pregnancy? J Perinat Med. 2015;43(6):667–674.
- Gonsalkorala ES, Cannon MD, Lim TY, et al. Non-invasive markers (ALBI and APRI) predict pregnancy outcomes in women with chronic liver disease. Am J Gastroenterol. 2019;114(2):267–275.
- Cui D, Zhong Y, Zhang L, et al. Bile acid levels and risk of adverse perinatal outcomes in intrahepatic cholestasis of pregnancy: a meta‐analysis. J Obstet Gynaecol Res. 2017;43(9):1411–1420.
- Lee RH, Kwok KM, Ingles S, et al. Pregnancy outcomes during an era of aggressive management for intrahepatic cholestasis of pregnancy. Amer J Perinatol. 2008;25(6):341–345.
- Mays JK. The active management of intrahepatic cholestasis of pregnancy. Curr Opin Obstet Gynecol. 2010;22(2):100–103.
- Biberoglu E, Kirbas A, Daglar K, et al. Role of inflammation in intrahepatic cholestasis of pregnancy. J Obstet Gynaecol Res. 2016;42(3):252–257.
- Kirbas A, Biberoglu E, Daglar K, et al. Neutrophil-to-lymphocyte ratio as a diagnostic marker of intrahepatic cholestasis of pregnancy. Eur J Obstet Gynecol Reprod Biol. 2014;180:12–15.